FOFredmoore Legaspi Orosco

Fredmoore Legaspi Orosco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fredmoore Legaspi Orosco has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A novel V236I substitution in the β-tubulin isotype 1 gene of Ancylostoma ceylanicum is associated with reduced in silico benzimidazole-binding affinity

    by Jan Clyden B. Tenorio, Ian Kim B. Tabios, Jose Ma. M. Angeles, Maria Mardalena Martini Kaisar, Mark Andrian B. Macalalad, Fredmoore L. Orosco, Prasert Saichua, Sutas Suttiprapa

    Background and Aim: Benzimidazoles (BZ) remain the cornerstone of soil-transmitted helminth control programs; however, the emergence of resistance-associated mutations in the β-tubulin gene threatens their long-term effectiveness. Information on BZ resistance markers in hookworms from Southeast Asia remains limited. This study investigated the occurrence of β-tubulin isotype 1 mutations in hookworms from the Philippines and Indonesia and evaluated the potential effects of detected variants on BZ binding and tubulin dimerization using in silico analyses. Materials and Methods: Eighteen archived hookworm-positive fecal samples collected from the Philippines (n = 13) and Indonesia (n = 5) were analyzed. Molecular speciation was performed using species-specific genetic markers, followed by amplification and sequencing of the β-tubulin isotype 1 gene regions that encompass known BZ resistance codons. Identified variants were subjected to in silico molecular docking, molecular dynamics simulations, binding free-energy calculations, and protein–protein interaction analyses to assess their effects on drug binding and tubulin dimer formation. Results: Fifteen samples were identified as Necator americanus and three as Ancylostoma ceylanicum. No canonical BZ resistance-associated mutations were detected at codons 134, 167, 198, or 200. However, two A. ceylanicum isolates from the Philippines carried a novel V236I substitution resulting from a GTC→ATC nucleotide change. Molecular docking demonstrated minimal alterations in docking poses, whereas molecular dynamics simulations revealed a marked reduction in BZ-binding favorability in the mutant protein. The V236I variant exhibited substantially lower MM-GBSA binding free-energy with albendazole than the wild-type protein (−13.34 vs. −33.42 kcal/mol), accompanied by reduced hydrogen-bond formation. Structural analyses suggested that the bulkier isoleucine side chain may introduce steric hindrance within the binding region, thereby weakening ligand–protein interactions. In contrast, the mutation produced negligible effects on tubulin dimer stability, binding affinity, and conformational dynamics. Conclusion: A novel V236I substitution was identified in A. ceylanicum from Southeast Asia and was predicted to reduce BZ-binding efficiency through steric and energetic effects while preserving tubulin dimer integrity. These findings highlight V236I as a potential BZ resistance-associated variant and emphasize the need for continued molecular surveillance and experimental validation of emerging resistance markers in hookworm populations. Keywords: albendazole, Ancylostoma ceylanicum, benzimidazole resistance, β-tubulin, hookworm, molecular dynamics, soil-transmitted helminths, Southeast Asia.

  • Discovery of Novel Red Algal Inhibitors Targeting African Swine Fever Virus dUTPase through Integrated Computational Screening

    by Razel F. Melendez, Christelle Jane C. Muyano, Mark Andrian B. Macalalad, Fredmoore L. Orosco

    Introduction: African swine fever virus (ASFV) is the causative agent of African swine fever, a highly lethal disease affecting domestic pigs and wild boars. Despite its first identification in East Africa in the early 1900s, no effective therapeutic drugs or vaccines are currently available. This study investigates the inhibitory potential of red algae-derived compounds against ASFV dUTPase, a key enzyme that prevents uracil misincorporation during viral DNA synthesis and maintains ge-nome fidelity. Methods: Red algal compounds were curated from an extensive database and subjected to ADMET analysis to evaluate their pharmacokinetic properties. Binding interactions with ASFV dUTPase were analyzed using a consensus docking approach. Molecular dynamics simulations and binding free en-ergy calculations were then conducted to assess the stability and energetic favorability under swine physiological conditions. Off-target docking was performed to identify potential interactions with swine dUTPase and evaluate safety. Results: Among the compounds tested, thyrsenol A and 14-keto-dehydro-thyrsiferol, isolated from two Laurencia species, were identified as promising inhibitors of ASFV dUTPase. Both compounds demonstrated stable binding interactions with the target protein and strong binding affinities. Analy-sis of RMSD, RMSF, and hydrogen bond profiles further supported their stability. Off-target analysis indicated a low likelihood of interfering with swine dUTPase function. Conclusion: These findings highlight red algae as a potential source for developing anti-ASFV ther-apeutics and pig feed supplements. Further in vitro and in vivo studies are warranted to validate these results and explore their practical applications in disease control.

  • Open Access

    Pan-viral efficacy profile of ribavirin: quantitative potency and safety landscape across virus families

    by Fredmoore Orosco

    This study quantifies ribavirin’s pan-viral efficacy across seven virus families, compares it with favipiravir and remdesivir, and evaluates viral trait predictors alongside clinical concordance. In vitro analyses showed the highest potency against Flaviviridae and Paramyxoviridae, whereas Coronaviridae and Astroviridae were less susceptible, consistent with proofreading polymerases. Compared with its peers, remdesivir was most potent in coronavirus and filovirus models, while favipiravir exhibited the widest therapeutic window in orthomyxovirus assays. Family-wise means and bootstrap trait modeling identified the presence of a proofreading polymerase as the strongest positive predictor of log EC 50 , with negative-sense genomes also associated with reduced susceptibility. Clinical evidence aligned with laboratory findings, demonstrating robust benefits in hepatitis C and Lassa fever, with mixed effects in respiratory infections. Overall, the results provide an actionable benchmark for broad-spectrum drug selection and prioritization in preparedness and outbreak response.


  • Antiviral Potential of Brown Algal Metabolites Against A179L Anti-apoptotic Protein: A Computational Strategy for African Swine Fever Treatment

    by Mark Andrian B. Macalalad, Fredmoore L. Orosco

    Introduction/Objective: African swine fever virus poses a persistent threat to the global pork industry owing to its severe impact on animal welfare, the economy, and food security. Currently, no antiviral medicines are available, and biosecurity measures, such as quarantine and culling, have proven insufficient, often resulting in further economic losses. Given the widespread impact of ASFV, there is an urgent need to explore and develop new treatment strategies to mitigate its spread. Methods: 1,212 secondary metabolites from brown algae were screened using ADMET profiling. Compounds with favorable properties were selected for molecular docking against A179L, an antiapoptotic protein of ASFV. The top-scoring metabolites were further analyzed through molecular dynamics simulations, principal component analysis (PCA), and binding energy calculations. Results: ADMET profiling identified compounds with drug-like pharmacokinetic properties. Consensus molecular docking using two docking programs predicted the binding poses of the metabolites, and the top ten candidate ligands with the strongest docking scores were selected. We then performed 300 ns molecular dynamics simulations to assess the stability of the protein-ligand complexes, which were further validated through Principal Component Analysis (PCA). Finally, binding energies were estimated using both MMPBSA and MMGBSA approaches, and the key residues involved during binding were identified. All ten final candidate ligands demonstrated stability and favorable binding affinity (-27.78 kcal/mol to -38.58 kcal/mol). Conclusion: Five compounds (CID: 24796376, sargachromanol G, strictaepoxide, CID: 163107957, and saringosterone) with the strongest binding energies are recommended for in vitro and in vivo testing to validate their potential as therapeutic agents against ASFV.


  • Open Access

    Marine fungal metabolites as antiviral agents: Computer-aided drug screening for selective inhibition of African swine fever virus dUTPase

    by Mark Andrian B. Macalalad, Fredmoore L. Orosco

    Introduction: African swine fever (ASF) continues to be a significant threat to the global livestock industry due to its severe impact on pig populations. Currently, there are no approved therapeutic agents for the virus, and biosecurity measures such as culling have led to substantial economic losses. In light of its effects on food security and the economy, our study aims to identify potential antiviral compounds from marine fungal metabolites that target the dUTPase enzyme of the African swine fever virus (ASFV). Methods: We screened 4,683 marine fungal metabolites using a series of virtual screening techniques. These included ADMET profiling to assess drug-likeness, consensus molecular docking to predict preferred docking poses and rank the docking scores, 300 ns molecular dynamics (MD) simulations to determine stability, principal component analysis (PCA) to verify simulation convergence, and MMPB(GB)SA analysis to estimate binding affinity. Results: Of the 4,683 compounds, 328 passed our ADMET filter, and the 10 highest-scoring ligands from molecular docking were evaluated for stability and binding affinity against both swine and ASFV dUTPase. Among the candidates, tricycloalternarene C (M1421), derived from Alternaria sp., emerged as a promising candidate. It exhibited excellent drug-likeness, stability, and binding affinity comparable to the three control compounds, while showing less affinity towards the swine dUTPase. Conclusion: Tricycloalternarene C holds potential as a selective inhibitor of ASFV dUTPase. We recommend further experimental validation to confirm its efficacy as an antiviral agent against African swine fever.


  • Reverse vaccinology-aided design of an epitope-based subunit vaccine against classical swine fever virus

    by Edward C. Banico, Ella Mae Joy S. Sira, Lauren Emily Fajardo, Nyzar Mabeth O. Odchimar, Fredmoore L. Orosco


  • Open Access

    Design and evaluation of a multi-epitope subunit vaccine against human norovirus using an immunoinformatics approach

    by Zxcy L. Nonog, Edward C. Banico, Ma. Easter V. Sajo, Pablo V. Serrano, Fredmoore L. Orosco

    Objectives: This study aimed to identify safe, conserved, and highly immunogenic epitopes from all proteins of human-infecting norovirus (NoV) and to design a multi-epitope subunit vaccine construct from these epitopes using an immunoinformatics approach. Additionally, the vaccine construct was evaluated using both sequence- and structure-based assessments.Methods: Conserved fragments were identified from all proteins of human-infecting NoV, and B and T lymphocyte epitopes were subsequently predicted using multiple epitope prediction tools. The selected epitopes were linked to form a multi-epitope construct, incorporating various adjuvants in the design. Vaccine constructs with different adjuvants were analyzed for their physicochemical properties and immune simulation profiles, and the optimal combination was selected as the final vaccine candidate for further study. Finally, molecular docking and dynamics simulations were performed to visualize the interaction between the construct and a host immune receptor.Results: Twenty-two safe, conserved, and highly immunogenic epitopes were identified from all human-infecting NoV proteins. The construct adjuvanted with 50S ribosomal protein L7/L12 (50SrpL7/L12) was chosen as the final vaccine candidate due to its optimal physicochemical properties and favorable immune simulation profile. Furthermore, the construct exhibited high binding affinity and a stable interaction with toll-like receptor 4).Conclusion: The multi-epitope subunit vaccine designed in this study shows promise as a potential NoV vaccine candidate for human immunization. Further in vitro and in vivo experiments are warranted to validate these findings.


  • n silico approach for designing a pan-proteomic and pan-genotypic hepatitis C virus multi-epitope subunit vaccine

    by Nyzar Mabeth Odchimar, Ella Mae Joy Sira, Edward Banico, Alea Maurice Simbulan, Fredmoore Orosco

    Hepatitis C Virus (HCV) is the most infectious hepatitis virus and the leading cause of liver-related mortality. The lack of a vaccine, combined with HCV’s hypervariability, contributes to this global health concern; thus, there is an urgent need for a potent, cross-protective vaccine. With the aid of computational vaccinology, we aimed to design and evaluate multi-epitope vaccines based on highly conserved epitopes from multiple proteins across 8 recognized HCV genotypes and 47 subtypes. The designed HCV vaccine constructs (VC) are composed of antigenic, non-allergenic, non-toxic, non-human homologues, and conserved epitopes within the structural and non-structural HCV proteins, linked with proper adjuvants and linkers. The final HCV VC had an instability index of 33.69. Tertiary structure validation of the modelled HCV VC revealed a high-quality protein. Molecular docking, molecular dynamic simulations, and Molecular Mechanics/Poisson–Boltzmann Surface Area (MM/PBSA) and General Born Surface Area (MM/GBSA) calculations demonstrated a strong and stable binding interaction between the HCV VC and immune receptors (TLR2, 3, and 4). The final HCV VC-TLR3 is the best docking complex (-226.61 kcal/mol) with a highly stable binding affinity in the entire 200 ns molecular dynamics simulation. Notably, immune simulation revealed that HCV VC elicited a high antibody level and stronger IFN-ɣ and IL-2 levels compared to reference studies. This study designed a novel multi-epitope HCV VC that could provide a stronger immune response and cross-protection against hypervariable HCV that requires further in vitro validation.